Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

UBS Lifts United Therapeutics Price Target Amid Positive Study Results

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 9/2/2025, 11:32 am ET | 4 min
UBS Lifts United Therapeutics Price Target Amid Positive Study Results Thumbnail

In this article Last trade Sep, 02 12:21 PM

  • UTHR+35.84%
    UTHR - NYSEUnited Therapeutics Corporation
    $414.00+109.24 (+35.84%)
    Volume:  1.93M
    Float:  40.57M
    $402.28Day Low/High$465.00

United Therapeutics Corporation stocks have been trading up by 36.91 percent amid positive sentiment from promising FDA designations.

Candlestick Chart

Live Update At 11:32:19 EST: On Tuesday, September 02, 2025 United Therapeutics Corporation stock [NASDAQ: UTHR] is trending up by 36.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview

United Therapeutics Corporation is making waves in the stock market strengthening investor confidence with recent financial performance. The company’s recent earnings revealed a robust operating revenue of nearly $799M in the latest quarter, marking a steady climb in its annual revenue trend. Behind the scenes, key figures like EBITDA standing proud at $436.8M and Gross Profit solidifying at $711M paint a picture of strength.

The firm’s no-debt situation further underscores its financial fortitude. With total liabilities weighing in at a mere $734.4M against assets of $7.9B, the company’s financial architecture reflects stability. A high return on equity ratio of 19.3% is indicative of commendable management effectiveness. In simple terms, what this means is that United Therapeutics knows how to turn its investments into growth and profit effectively.

Data reveals smooth sailing in the financial waters. Consistently high profit margins and intriguing cash flow metrics, peppered by free cash flow figures dancing around $129.5M, underscore the positive sentiment analysts currently hold.

Market Reactions: Confidence on the Rise

The market reacted zealously to these revelations. The latest boost from analysts coincides directly with positive signals thrown off by their Tyvaso trials. UBS raising the price target is no small thing, strongly backing the company’s hopeful outlook for the treatment. This strategic pivot towards advanced therapeutic studies is setting the stage for profound growth potential.

Backed by this study, United Therapeutics is set to penetrate innovative medical niches firmly. This step isn’t just about tackling diseases; it’s a bold vision to harness new scientific heights. The stock’s behavior, catapulting swiftly, mirrors the vibe buzzing around its wall street stance.

More Breaking News

Conclusion and Outlook

Both the pre-and post-market murmurs echo the sentiment: United Therapeutics is on an upward trajectory with promising opportunities. Alphabets of growth potential line up neatly in its plans for medical market expansion. Each market participant—investor, analyst, or trader—is taking a keen interest, assessing how this growth could potentially inflate stock values further. Anticipations are that United Therapeutics will continue rolling out new breakthroughs, solidifying this buoyed investor confidence.

The shifted narrative with UBS’s price target uplift is crystallizing a promising scenario offering sustainable growth in financials and market cap. In the world of trading, staying vigilant is crucial. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Maintaining its course with resilient operating cash flow and stalwart investment avenues, United Therapeutics stands resilient and ready to take on both traders’ and analysts’ expectations. With the ball firmly in its court, it looks set to play out this promising performance into a scoreboard win on the stock exchange.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

In this article (YTD Performance)

  • UTHR-13.63%
    UTHR - NYSEUnited Therapeutics Corporation
    $414.00+109.24 (+35.84%)
    Volume:  1.93M
    Float:  40.57M
    $402.28Day Low/High$465.00

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Get Tim Sykes’ Daily Trade Ideas for $0
Claim Free Alerts

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications